Nortion Medical's globally unique CE dual-certified composite steep pulse therapy device will make its debut at the 2026 EAU! The minimally invasive ablation for both prostate cancer and benign prostatic hyperplasia has attracted global attention!
From March 13th to 16th, 2026, the 41st Annual Congress of the European Association of Urology (EAU 2026) was grandly held in London. As the world's top event in the field of urology, the conference featured over 300 cutting-edge forums and surgical demonstrations, focusing on three core trends:
◼ Precise diagnosis and treatment：Optimizing clinical decision-making through radiomics/AI models (such as MRI stratification for prostate cancer)
◼ Minimally invasive function preservation：Technological innovations such as IRE and TULSA enhance patients' quality of life
◼ Chinese Innovation Power：Multi-center Research Driving Paradigm Shift in Treatment
At the EAU, a technological extravaganza, Novation Medical made a stunning appearance with its compound steep pulse therapy device, the only one in the world to hold both CE certifications (for prostate cancer and benign prostatic hyperplasia indications). The booth was crowded with visitors, and experts from over 20 countries deeply experienced the technological highlights:
◼ Precise positioning：Equipped with a puncture frame and disposable ablation electrode needle, achieving millimeter-level ablation control
◼ Advantages of non-thermal ablation：Prostatic capsule + potato demonstration visually demonstrates zero thermal damage characteristics of vascular/nerve structures
◼ Operational convenience：Under the guidance of portable ultrasound, only puncture experience is required to quickly grasp the technique
Irreversible electroporation (IRE) technology has become the focus of the entire audience due to its unique advantages:
◼ Complete ablation：100%clear boundary, 100% cell apoptosis within the area
◼ Functional preservation：The tissue selectivity has no significant damage to the urethra, nerves, and blood vessels, protecting urinary control and sexual function
◼ Minimally invasive characteristic：only leaving several 1mm-diameter wounds with almost no bleeding
◼ Few complications：Non-thermal ablation does not damage the rectum, eliminating the risk of rectal fistula
◼ Long-term efficacy verification：Five-year follow-up data after prostate cancer surgery demonstrates solid strength
Nortion Medical's internationalization strategy achieves a milestone breakthrough：
◼ Access breakthrough：Obtained medical device circulation licenses in Indonesia, Türkiye, and Thailand
◼ Clinical implementation：Routine surgeries have been carried out in Türkiye, the Philippines, and Malaysia
◼ Cooperation expansion：Dealer signing has been completed in the Middle East region
◼ Strategic advancement：In-depth negotiations are underway in Europe, South America, Southeast Asia, and other regions
We look forward to establishing deep cooperation with global distributors to jointly explore local channels. At the same time, we respect and support the development of other partners in their respective advantageous markets, achieving complementarity.
As urology enters a new phase of individualized treatment, Nortion Medical will continue to deepen its global deployment of IRE technology, leveraging cutting-edge technology to achieve the perfect unification of the "impossible triangle" in prostate disease treatment - radical lesion removal, functional preservation, and minimally invasive experience!
